a Chemotherapeutics for the treatment of tumorigenic conditions that feature novel modes of action are highly sought after to overcome the limitations of current chemotherapies. Herein, we report the conjugation of the alkylating agent chlorambucil to the RAPTA scaffold, a well-established pharmacophore.
Introduction
Alkylating agents have dominated cancer chemotherapy for many years, and among many examples of alkylating agents that have been approved for cancer treatment, the nitrogen mustard, chlorambucil (Chart 1), is one of the classic anticancer drugs. [1] [2] [3] Chlorambucil is administered orally 4 and has been mainly used in the treatment of chronic lymphocytic leukemia, but may also be used in the therapy of tumors, such as certain types of non-Hodgkin lymphoma, trophoblastic neoplasms, and ovarian carcinoma. This compound class exhibits its mode of action through the alkylation of the N7 atoms of guanine or adenine as well as N3 of adenine in double helical DNA, which consequently inhibits cell proliferation. 5, 6 Platinum complexes are often also considered as alkylating agents as they form coordination bonds to DNA nucleobases. 2, 7 The potency of platinum complexes in chemotherapy is unprecedented and they are used to treat many types of tumors. [8] [9] [10] [11] However, their disadvantages, in particular, resistance development and side effects, have driven the development of metal complexes comprising metal centers other than platinum. [12] [13] [14] Ruthenium compounds take a prominent position in this development process, as two compounds have entered clinical trials. [15] [16] [17] Organometallic RAPTA complexes are among the most promising ruthenium-based compounds in preclinical development and although they are essentially non-cytotoxic in cancer cell lines, they have demonstrated anticancer activity in vivo. [17] [18] [19] [20] The RAPTA framework (Chart 1) consists of a ruthenium center, an η 6 -coordinated arene, typically p-cymene (RAPTA-C) or toluene (RAPTA-T), the 1,3,5-triaza-7-phosphaadamantane (PTA) ligand and two chlorido leaving groups. 19, 21 The RAPTA scaffold can be equipped with functionalities that provide specific properties. For example, derivatization of the arene ligand with ethacrynic acid resulted in efficient glutathione-S-transferase inhibitors. 22 The mode of action appears to involve the enzymatic cleavage of the enzymeinhibiting moiety from the metal fragment allowing the metal moiety to target other biomolecules. This represents an example of a multi-targeted anticancer agent with components of the same molecule interacting with different targets. 23 Such drugs are designed to act against several individual molecular targets rather than a single enzyme or DNA as the target for platinum anticancer drugs. 24 This approach offers a number of advantages such as tuneable pharmacological properties and anticancer activity, and altered metabolism and resistance development. 23, 25 An alternative approach for developing ruthenium-arene multitargeted compounds is through the coordination of a bioactive ligand to the metal center as shown for Ru II (cym) (cym = η 6 -p-cymene) complexes of 3-hydroxyflavones, [26] [27] [28] lapachol, 29 paullone, 30 and lonidamine 31 derivatives and other examples. 32 Such an "intramolecular"
combination therapy may also help to overcome disadvantages and limitations of antineoplastic alkylating agents. Therefore, we have designed a new compound class that features the RAPTA framework conjugated with chlorambucil. Such compounds should be able to alkylate DNA and at the same time coordinate to proteins through the ruthenium center while maintaining the structure of the RAPTA pharmacophore. This approach is supported by the observation that RAPTA binds preferentially to proteins through coordination, as shown in crystallographic experiments using the nucleosome core particle (NCP) in which the RAPTA scaffold was found predominantly at the histone proteins. 33, 34 The synthesis of alkylating RAPTA derivatives was complemented by studies on the cytotoxic activity in human cancer cell lines and mass spectrometric investigations with 9-ethylguanine (EtG) and L-histidine (His), L-methionine (Met) and ubiquitin (Ub) as DNA and protein models, respectively.
Experimental

Materials
Solvents were purified and degassed prior to use. 35 All compounds were obtained from Sigma-Aldrich except for L-histidine which was obtained from Merck; formic acid was from Fluka; 9-ethylguanine and tetramethylammonium acetate were from TCI Europe. glucose and glutamax, and were supplemented with 10% heatinactivated fetal bovine serum and antibiotics. Cultures were maintained at 37°C under a humidified atmosphere containing 6% CO 2 . All cell culture reagents were purchased from Gibco-BRL, Basel, Switzerland. For cell viability experiments tests, cells were grown on 96-well plates (Costar, Integra Biosciences, Cambridge, MA, USA) as monolayers for 24 h in complete medium with 10% FCS to reach sub-confluence. Then fresh complete medium with 5% FCS was added together with the drugs, and the culture was continued for another 72 h. The compounds were pre-dissolved at 20 mM in DMSO and then added to the cell culture medium at the required concentration with a maximum DMSO content of 0.5%, v/v, to be incubated for 72 h. At these concentrations, DMSO has no effect on cell viability. Cell viability was determined using the MTT assay, which quantifies the mitochondrial activity in metabolically active cells, essentially as reported previously. 36 Briefly, following drug exposure, MTT (Sigma, final concentration 0.2 mg ml −1 ) was added to the cell culture medium for the final 2 h, and then the culture medium was aspirated and the violet formazan precipitate dissolved in 0.1 M HCl in 2-propanol. The optical density, which is directly proportional to the number of surviving cells, was quantified at 540 nm using a multiwell plate reader (iEMS Reader MF, Labsystems, USA) and the percentage of surviving cells was calculated from the absorbance of untreated cells. [Dichlorido(η (7). Similar to 6, compound 7 was prepared by reacting 4 (100 mg, 0.09 mmol) with 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3. 
Protein and DNA binding studies
Complex 6 (25 µM) was incubated at 37°C in 1% DMSO-water or in 1 mM tetramethylammonium acetate with 9-ethylguanine (EtG) or ubiquitin (Ub) at metal-to-biomolecule ratios of 1 : 2 and 1 : 1, respectively. Complex 6 was also incubated with both EtG and Ub at molar ratios of 1 : 2 : 1 and 2 : 8 : 1 giving a final protein concentration of 25 µM. Aqueous solutions of 6 were analyzed for comparison purposes under the same conditions as the biomolecule-containing reaction mixtures. In a further set of experiments, histidine (His) and methionine (Met) were separately preincubated with 6 for 1 h in buffered solution prior to the addition of EtG giving a final molar ratio of 2 : 1 : 4. Prior to analysis, the incubation mixtures were diluted with water 1 : 5 in the case of the low-molecular weight biomolecules and 1 : 1 for ubiquitin-containing samples, corresponding to 5 µM complex and 12.5 µM protein, respectively. Protein samples were analyzed under non-denaturing conditions. To characterize the adducts formed between 6 and the biomolecules, full mass spectra were recorded in the m/z range of 70-2500 on a Bruker Maxis UHR qTOF (capillary −4500 V, dry gas 6.0 l min −1 , nebulizer 0.6 bar, dry temperature 180°C), and collision-induced MS n experiments were conducted on a Bruker Amazon SL ion trap under similar source conditions. Data analysis was done with the Bruker data analysis software ESI Compass 1.3 and DataAnalysis 4.0 (build 234). Protein mass spectra were deconvoluted using the maximum entropy deconvolution algorithm with automatic data point spacing and 30 000 resolving power.
Results and discussion
We decided to combine the RAPTA pharmacophore, which has a ruthenium(II) center able to bind to histone proteins, 33, 34 with the alkylating moiety found in the anticancer drug chlorambucil 1, which is known to act as a DNA alkylating agent. 5, 6 The chlorambucil group was conjugated to the RAPTA scaffold by derivatization of the arene ring with chlorambucil via an amide bond to the piano-stool Ru complex. The PTA co-ligand was also varied with 3,7-diacetyl- . Finally, the dimers were treated with PTA, DAPTA or 3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-glucofuranoside to yield complexes 6-9. The compounds were characterized by NMR spectroscopy, mass spectrometry and elemental analysis. 31 P{ 1 H} NMR spectroscopy was used to monitor the formation of complexes 6-9. In these spectra a shift from ca. −100 to −33 ppm, from −78 to −17 ppm and from 119 to 133 ppm was observed for the 31 P nuclei in the PTA, DAPTA and phosphite ligands, respectively, upon coordination to the ruthenium center. In addition, characteristic shifts in the 1 H NMR spectra were observed, as reported for similar types of complexes, 40, 41 confirming the proposed structures of the complexes. Compounds 6-9 are stable in CDCl 3 and DMF solution and no decomposition or release of the arene moiety was observed.
The cytotoxicity of the chlorambucil-functionalized RAPTAtype complexes (6-9) was evaluated on human ovarian cancer (A2780) cells, their cisplatin-resistant variant (A2780R) and a human breast cancer (MCF7) cell line. In addition, studies mixing chlorambucil and RAPTA-T at a molar ratio of 1 : 1, as the closest structural analogue to 6-9, were conducted and compared to RAPTA-T as the parent compound (Table 1) . In general, most of the compounds were more active in the ovarian cancer cell lines than in MCF7. While RAPTA-T is not cytotoxic under the applied conditions in the three cell lines, the chlorambucil-functionalized complexes are active in the low µM range. Both chlorambucil 1 and a 1 : 1 mixture of RAPTA-T with 1 show similar cytotoxicity profiles to complexes 6-9 suggesting that the alkylating agent determines the cytotoxicity of the complexes. Notably, 1 and a 1 : 1 mixture of RAPTA-T with 1 show virtually identical IC 50 values in the cell lines. This is not surprising given the fact that RAPTA compounds are not cytotoxic. Furthermore, the nature of the phosphorus donor co-ligand is of low importance with the exception of 7 in MCF7 cells. The cytotoxicity decreases in all cell lines for 6 over 9. This may be related to 9 having a longer linker between the chlorambucil moiety and the arene moiety and being therefore more flexible than 6 and 9. In the A2780 and MCF7 cell lines there does not appear to be any advantage in conjugating 1 with a RAPTA fragment, whereas in the cisplatin-resistant cell line A2780R, complexes 6-8 are considerably more potent than 1 and the mixture of 1 with RAPTA-T. This observation suggests that conjugation of 1 to Ru(arene) compounds, irrespective of the phosphorus donor co-ligand, provides a means to overcome cisplatin-induced resistance mechanisms in cancer cells.
Compound 6 was selected for stability studies and subsequent experiments to demonstrate the cross-linking ability of biomolecules as it possesses the optimum cytotoxicity properties of the compound series and also reasonably soluble in aqueous solution. Furthermore, the experiments are not interfered by the instability of the DAPTA ligand in 7 or the complicated hydrolysis pathways of the glucose-derived phosphite in 8.
41
Initially, the hydrolysis behavior of 6 was studied after dissolving the compound in 1% DMSO-water. Immediate analysis showed the presence of a single peak in the ESI mass spectrum at m/z 688.0891, which was assigned to the ion [M − Cl] + (see Table 2 for experimental and simulated mass signals; Scheme 2). The same mixture was analyzed over a period of 2 days revealing that 6 starts to hydrolyze, to some extent, after incubation for 1. (Fig. 1B) . There was no further change in the mass spectrum from 21 to 72 h. In order to characterize this species further, collision-induced tandem mass spectrometric experiments were conducted using L 2OH at m/z 357.1 as the precursor ion. A monohydroxyl L OH ion was detected at m/z 340.1, together with an amide-cleaved product ion at m/z 250.1 and neutral loss products at m/z 232.1 (-H 2 O) and 214.0 (-2H 2 O), all underlining the identity of the parent mass signal. Hydrolysis of 6 in tetramethylammonium acetate buffer is similar to that observed in water. Hydrolysis products of intact 6 are observed after 10 min, including an additional acetate adduct [6 − 2Cl + CH 3 COO] + from the buffer as the most abunScheme 1 Synthetic route to the chlorambucil-functionalized ruthenium complexes with amphiphilic phosphorus-based co-ligands. Compound 6 was designed with the aim to provide a compound able to alkylate DNA and simultaneously coordinate to proteins. In order to demonstrate the ability of 6 to cross-link, its reactivity was investigated with the DNA model nucleobase EtG and His and Met as protein building blocks. Thus, 6 was incubated with EtG (1 : 2), His or Met (1 : 2) and with both (6 : EtG : His/Met = 1 : 4 : 2) and the solutions were analyzed by ESI-TOF mass spectrometry.
Incubation of 6 with EtG in water resulted immediately in the detection of several EtG-ruthenium adducts besides the mass signals caused by hydrolysed 6. Accordingly, monochlorido, mono-hydroxido and EtG coordination adducts were observed for hydrolysed 6, e.g. (Fig. 1C) . Therefore, it seems that the DNAalkylation reaction with the chlorambucil fragment is much slower than the hydrolysis and complexation reactions of the ruthenium ion. Based on this hypothesis it is possible to distinguish EtG complexation from EtG alkylation. In tetramethylammonium acetate buffer (1 mM), the peak assigned to [6 − 2Cl − H + EtG] + was detected after 15 min in 54% relative abundance. In light of the observations made in water, this peak is assumed to be due to the coordination of EtG to the ruthenium center rather than an alkylation product. Unreacted and hydrolyzed 6 were also detected in the forms of [6 − 2Cl + CH 3 In an attempt to saturate the hydrolyzed coordination sites at the ruthenium center in 6 prior to incubation with EtG in buffer, the compound was preincubated with 2 equivalents of His or Met for 1 h. Analysis of the reaction mixtures revealed the formation of [ 
2H]
+ was observed in the TOF mass spectra at m/z 930.3142 in low abundance. However, this species was not detected in the MS n fragmentation spectra. Thus, it appears that amino acid coordination and simultaneous EtG alkylation is possible, but only to minor extents. Hydrolysis of the metal-chloride bonds and coordination of biomolecules take place within several hours whereas alkylation requires longer reaction times. Therefore, stabilization of the metal-arene coordination is crucial for a synergistic antiproliferative activity. It appears that the presence of small nucleophilic molecules, e.g. EtG, His or Met, may stabilize the coordination of the arene to the ruthenium and the formed products were stable over several days. Moreover, the PTA remains tightly coordinated as well, so that the RAPTA core remains intact. Increased pH conditions also seem to increase the reaction kinetics for both hydrolysis/coordination and alkylation.
Complex 6 was also incubated with ubiquitin (2 : 1) or with a mixture of EtG and Ub (2 : 4 : 1) in water and tetramethylammonium acetate (1 mM). Ubiquitin is a low molecular weight protein well-suited for MS experiments and ruthenium arene complexes are known to coordinatively bind to it. 42 Incubation of 6 with Ub showed a similar hydrolysis behavior to that observed in the stability studies and only very minor adducts were observed even after 69 h of incubation, mainly corresponding to Ru(PTA)Cl and Ru(PTA)(DMSO) adducts. Fewer 6-Ub adducts were observed in the presence of 2 equivalents of EtG in the reaction mixture. However, after 69 h, an adduct between hydrolyzed 6 and EtG is observed at m/z 829 which was also detected during incubation with EtG alone. (Fig. 3) , showing that the compound may cross-link a DNA base with a protein, albeit in low yield. The reaction of 6 with Ub in tetramethylammonium acetate proceeds similarly to water. However the reaction appears to be more selective. In the presence of EtG, adduct formation is similar, yielding the Ru(PTA)(DMSO) adduct as the most prevalent species and after 44 h a mass signal corresponding to [L OH − Cl + EtG] + is clearly observed.
The molar ratio of EtG was increased to 8 equivalents with respect to 6 during the reaction with Ub in buffered water. This did not influence the extent and the type of adducts. However, several small molecules formed featuring the characteristic ruthenium isotope pattern. Among these were several DMSOstabilized species with up to two coordinated EtG, which underwent release of the arene, and accordingly, free underline the alkylation of EtG. The mass-to-charge ratio suggests again that this species would be +3 charged, which is decreased to +1 by the addition of hydroxide and loss of a proton.
Conclusions
The combination of more than one pharmacophore has been shown to be a useful strategy for improving the anticancer activity of compounds with modes of action different from those of established drug compounds. Herein, we described the modification of a RAPTA complex with chlorambucil and the variation of the co-ligands and the distance between the Ru moiety and the alkylating agent chlorambucil. This strategy led to compounds with in vitro anticancer activity in the low µM range, being superior in cisplatin resistant cancer cells to chlorambucil, RAPTA-T or a mixture of both. Mass spectrometry studies showed that the η 6 -arene in 6 slowly cleaves in solution, but is sufficiently stable to result in a different cytotoxic effect as compared to the combination of chlorambucil and RAPTA-T. Moreover, the coordination of EtG to 6 following hydrolysis proceeds more rapidly than alkylation of EtG by the chlorambucil fragment. Due to the instability of the ruthenium-arene bond, alkylation of EtG is mainly observed for the free ligand and is detected as an [ observed. Peaks assigned to cross-linked species indicate that the design strategy for such a compound is feasible. However, further refinement of the compound class is needed to increase the stability of the Ru-arene bond to obtain a higher extent of simultaneous protein ruthenation and DNA alkylation. The mass shift of 6 Da between the His and Met mass spectra suggests that these mass signals may be attributed to amino acid adducts. 
